Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A review and meta
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY(2022)
摘要
One possible side effect of thrombopoietin receptor agonists in immune thrombocytopenia is thrombosis. Our aim is to systematically review whether patients with ITP that were treated with a TPO-RA have an increased risk for thrombosis as compared to ITP patients without TPO-RA. Patients in the intervention group were required to receive TPO-RA therapy. The primary outcome was the incidence of thromboembolic events. Eleven studies were included in the pooled analysis. More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Ten out of 11 studies showed a relative risk greater than 1. However, none of these individual risk ratios was statistically significant. The meta-analysis showed a RR of 1.82 [95 % CI 0.78-4.24]. Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPORA treatments versus ITP patients without TPO-RA treatment.
更多查看译文
关键词
Immune thrombocytopenia, Thrombopoietin receptor agonist, Thrombosis, Eltrombopag, Romiplostim
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要